Wasatch Advisors LP increased its position in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 47.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 206,740 shares of the company's stock after acquiring an additional 66,887 shares during the quarter. Wasatch Advisors LP owned about 0.51% of RxSight worth $10,219,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the company. Amalgamated Bank boosted its position in shares of RxSight by 21.3% during the second quarter. Amalgamated Bank now owns 1,177 shares of the company's stock worth $71,000 after purchasing an additional 207 shares in the last quarter. Principal Financial Group Inc. lifted its holdings in RxSight by 0.7% during the third quarter. Principal Financial Group Inc. now owns 36,046 shares of the company's stock worth $1,782,000 after acquiring an additional 240 shares in the last quarter. Crossmark Global Holdings Inc. grew its stake in RxSight by 3.2% in the second quarter. Crossmark Global Holdings Inc. now owns 7,861 shares of the company's stock valued at $473,000 after acquiring an additional 242 shares during the period. RiverPark Advisors LLC grew its stake in RxSight by 9.6% in the second quarter. RiverPark Advisors LLC now owns 3,379 shares of the company's stock valued at $203,000 after acquiring an additional 297 shares during the period. Finally, CWM LLC raised its position in shares of RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company's stock worth $25,000 after purchasing an additional 371 shares during the period. Institutional investors and hedge funds own 78.78% of the company's stock.
RxSight Trading Up 1.0 %
Shares of NASDAQ:RXST traded up $0.48 during trading on Friday, hitting $46.88. 254,146 shares of the company were exchanged, compared to its average volume of 683,749. RxSight, Inc. has a fifty-two week low of $28.88 and a fifty-two week high of $66.54. The stock has a market cap of $1.89 billion, a price-to-earnings ratio of -56.48 and a beta of 1.19. The firm has a fifty day moving average price of $48.58 and a two-hundred day moving average price of $52.26.
Analysts Set New Price Targets
RXST has been the subject of a number of research reports. Wells Fargo & Company lowered their target price on RxSight from $68.00 to $54.00 and set an "overweight" rating for the company in a research note on Tuesday, August 6th. Oppenheimer dropped their price objective on shares of RxSight from $72.00 to $65.00 and set an "outperform" rating on the stock in a report on Tuesday, August 6th. Jefferies Financial Group began coverage on shares of RxSight in a research note on Tuesday, October 29th. They issued a "buy" rating and a $72.00 target price for the company. Needham & Company LLC reiterated a "buy" rating and set a $66.00 target price on shares of RxSight in a report on Friday, September 13th. Finally, Stifel Nicolaus cut their price target on RxSight from $70.00 to $65.00 and set a "buy" rating on the stock in a report on Tuesday, August 6th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, RxSight currently has a consensus rating of "Buy" and a consensus price target of $61.63.
Get Our Latest Stock Report on RXST
Insider Buying and Selling
In other RxSight news, insider Ilya Goldshleger sold 3,100 shares of the company's stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $45.00, for a total value of $139,500.00. Following the sale, the insider now owns 42,246 shares in the company, valued at $1,901,070. This represents a 6.84 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Shweta Maniar sold 3,782 shares of the firm's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $45.88, for a total value of $173,518.16. Following the completion of the sale, the director now directly owns 10,902 shares of the company's stock, valued at approximately $500,183.76. The trade was a 25.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 62,702 shares of company stock worth $3,059,197. Insiders own 9.36% of the company's stock.
RxSight Profile
(
Free Report)
RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Read More
Before you consider RxSight, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list.
While RxSight currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.